JP4827986B2 - ＩＲＥ−１αインヒビター - Google Patents

ＩＲＥ−１αインヒビター Download PDF

Info

Publication number
JP4827986B2
JP4827986B2 JP2010511418A JP2010511418A JP4827986B2 JP 4827986 B2 JP4827986 B2 JP 4827986B2 JP 2010511418 A JP2010511418 A JP 2010511418A JP 2010511418 A JP2010511418 A JP 2010511418A JP 4827986 B2 JP4827986 B2 JP 4827986B2
Authority
JP
Japan
Prior art keywords
ire
compound
hydrogen
mmol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010511418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529147A (ja
JP2010529147A5 (en:Method
Inventor
ジョン ブルース パタスン
デイビッド グレゴリ ロナーガン
ゲアリー エイ． フリン
チンピン ゼン
ペーター ブイ． パライ
Original Assignee
マンカインド コーポレ−ション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド コーポレ−ション filed Critical マンカインド コーポレ−ション
Publication of JP2010529147A publication Critical patent/JP2010529147A/ja
Publication of JP2010529147A5 publication Critical patent/JP2010529147A5/ja
Application granted granted Critical
Publication of JP4827986B2 publication Critical patent/JP4827986B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/61—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/02—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/02—Thiols having mercapto groups bound to acyclic carbon atoms
    • C07C321/04—Thiols having mercapto groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/55—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C07C65/26—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/30—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/48—Aldehydo radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2010511418A 2007-06-08 2008-06-09 ＩＲＥ−１αインヒビター Expired - Fee Related JP4827986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94274307P 2007-06-08 2007-06-08
US60/942,743 2007-06-08
PCT/US2008/066310 WO2008154484A1 (en) 2007-06-08 2008-06-09 Ire-1a inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011012200A Division JP5684585B2 (ja) 2007-06-08 2011-01-24 ＩＲＥ−１αインヒビター

Publications (3)

Publication Number Publication Date
JP2010529147A JP2010529147A (ja) 2010-08-26
JP2010529147A5 JP2010529147A5 (en:Method) 2011-03-10
JP4827986B2 true JP4827986B2 (ja) 2011-11-30

Family

ID=39730581

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010511418A Expired - Fee Related JP4827986B2 (ja) 2007-06-08 2008-06-09 ＩＲＥ−１αインヒビター
JP2011012200A Expired - Fee Related JP5684585B2 (ja) 2007-06-08 2011-01-24 ＩＲＥ−１αインヒビター
JP2013169387A Ceased JP2014055129A (ja) 2007-06-08 2013-08-19 ＩＲＥ−１αインヒビター
JP2015005455A Expired - Fee Related JP5941173B2 (ja) 2007-06-08 2015-01-15 ＩＲＥ−１αインヒビター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011012200A Expired - Fee Related JP5684585B2 (ja) 2007-06-08 2011-01-24 ＩＲＥ−１αインヒビター
JP2013169387A Ceased JP2014055129A (ja) 2007-06-08 2013-08-19 ＩＲＥ−１αインヒビター
JP2015005455A Expired - Fee Related JP5941173B2 (ja) 2007-06-08 2015-01-15 ＩＲＥ−１αインヒビター

Country Status (8)

Country Link
US (5) US7858666B2 (en:Method)
EP (4) EP3150589A1 (en:Method)
JP (4) JP4827986B2 (en:Method)
CN (2) CN103450077B (en:Method)
CA (2) CA2963784A1 (en:Method)
ES (2) ES2601856T3 (en:Method)
MX (1) MX2009013332A (en:Method)
WO (1) WO2008154484A1 (en:Method)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011121964A (ja) * 2007-06-08 2011-06-23 Mannkind Corp ＩＲＥ−１αインヒビター

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140018354A9 (en) * 2009-07-23 2014-01-16 Nathaniel Moorman Inhibitors of mtor kinase as anti-viral agents
CA3042107C (en) * 2009-11-03 2023-03-07 Fosun Orinove Pharmatech, Inc. Ire-1.alpha. inhibitors
MX388981B (es) * 2010-04-05 2025-03-20 Fosun Orinove Pharmatech Inc Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
TWI622573B (zh) * 2010-11-05 2018-05-01 拜耳知識產權公司 藉由亞胺氫化製備經取代ｎ－（苄基）環丙胺之方法
WO2012109238A2 (en) * 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2012138715A2 (en) 2011-04-04 2012-10-11 Georgetown University Small molecule inhibitors of xbp1 splicing
PE20141201A1 (es) * 2011-08-19 2014-10-03 Glaxo Group Ltd Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
EP2841449B1 (en) 2012-04-23 2016-12-28 IMBA-Institut für Molekulare Biotechnologie GmbH Archease as rna ligase complex member
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
WO2015048331A1 (en) 2013-09-25 2015-04-02 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
CA2926571C (en) * 2013-10-08 2022-05-17 Qing-bin LU Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
JPWO2015136887A1 (ja) * 2014-03-10 2017-04-06 国立大学法人広島大学 滑膜細胞増殖抑制剤及び滑膜細胞の増殖抑制方法
US20160106721A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
EP3573608A1 (en) 2017-01-30 2019-12-04 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
CN106974908B (zh) * 2017-03-02 2019-11-12 深圳大学 含有hdac抑制剂和ire1抑制剂的药物组合物及用途
CN106822904B (zh) * 2017-03-08 2019-10-25 暨南大学 含akt抑制剂和ire1抑制剂的药物组合物及其应用
CN107308178B (zh) * 2017-07-31 2020-11-10 苏州大学附属儿童医院 一种用于肠外营养相关性肝病药物
BR112020019708A2 (pt) * 2018-03-27 2021-02-09 Neuropore Therapies, Inc. compostos como moduladores de sinalização de tlr2
JP2021529757A (ja) 2018-07-03 2021-11-04 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 小胞体ストレス応答の活性剤
WO2020019107A1 (en) * 2018-07-23 2020-01-30 Fosun Orinove Pharmatech, Inc. IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT
KR20210036374A (ko) * 2018-07-23 2021-04-02 포선 오리노브 파마테크, 인코포레이티드 암 치료를 위한 암 치료제와 조합된 IRE1α 억제제
AU2018447495A1 (en) * 2018-11-02 2021-06-17 Fosun Orinove Pharmatech, Inc. IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment
MX2021011596A (es) * 2019-03-26 2021-10-13 Neuropore Therapies Inc Compuestos y composiciones como moduladores de se?alizacion tlr.
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
CN118576600A (zh) * 2024-05-31 2024-09-03 中山大学附属第三医院 IRE1α抑制剂KIRA8在制备治疗复发难治多发性骨髓瘤的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56138179A (en) * 1980-02-04 1981-10-28 Anvar 2-nitronaphthofuran derivative, manufacture and cell growth regulant containing same
JP2001518890A (ja) * 1997-04-08 2001-10-16 サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク （セ エン エール エス） Ｈｉｖインテグラーゼの阻害剤としてのキノリン誘導体
WO2004037816A1 (en) * 2002-10-28 2004-05-06 Chugai Seiyaku Kabushiki Kaisha Benzofuran compounds having antitumor activity
JP2004534779A (ja) * 2001-05-30 2004-11-18 エルジー ライフサイエンス リミテッド 疾病治療用プロテインキナーゼ阻害剤
WO2007056155A1 (en) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators

Family Cites Families (399)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE209910C (en:Method) *
US675543A (en) 1899-08-05 1901-06-04 Farbenfabriken Elberfeld Co Derivatives of aromatic oxy-aldehydes and process of making same.
US2346662A (en) * 1940-04-08 1944-04-18 Universal Oil Prod Co Suppression of metal catalysis
US2282907A (en) 1941-05-01 1942-05-12 Us Rubber Co Parasiticide
US2649444A (en) 1948-10-19 1953-08-18 Burroughs Wellcome Co Process for the preparation of amino ketones
US2778853A (en) 1952-09-10 1957-01-22 Merck & Co Inc Deamination process
US2771391A (en) 1953-08-20 1956-11-20 Allied Lab Inc Physiologically active p-alkoxy-beta-piperidinopropiophenones causing cns depressantand anesthetic effects in animals
US2712031A (en) * 1953-10-27 1955-06-28 Lasdon Foundation Inc Monosubstituted salicylaldehyde alkoximes
US3080372A (en) 1960-03-25 1963-03-05 Res Lab Dr C Janssen 1-aroylalkyl-4-arylpiperidine derivatives
CH402859A (de) 1960-05-24 1965-11-30 Wander Ag Dr A Verfahren zur Herstellung von a-Pyrrolidino-valerophenonen
US3151124A (en) 1961-11-20 1964-09-29 Ciba Geigy Corp Alpha oxy-beta alkyl-gamma tertiary amino-alpha phenyl propanes
US3252996A (en) 1962-10-02 1966-05-24 Ciba Geigy Corp Alpha-pyrrolidinomethyl valero and caprophenones
BE633437A (en:Method) 1962-06-11
US3203962A (en) 1962-10-11 1965-08-31 Ciba Geigy Corp Alpha-phenyl-beta pyrrolidino-propiophenones
US3148997A (en) 1963-01-04 1964-09-15 Dow Chemical Co Catechol compounds in improving clays and clay-containing materials
US3211613A (en) 1963-01-14 1965-10-12 Merck & Co Inc Anticoccidial compositions and method of using same
FR1453234A (fr) 1964-02-18 1966-06-03 Pechiney Progil Sa Nouveaux composés fongicides à usage agricole
US3364210A (en) 1964-10-05 1968-01-16 American Cyanamid Co Substituted 3-aminoacrylophenones and method of preparing the same
CH445193A (de) 1964-12-14 1967-10-15 Agripat Sa Fungizides Mittel und seine Verwendung
FR1437423A (fr) * 1964-12-29 1966-05-06 Pechiney Progil Sa Composés fongicides nouveaux à usage agricole dérivés de l'aldéhyde salicylique
US3816433A (en) 1965-03-24 1974-06-11 Ferrosan Ab 4-fluoro-ypsilon-(4-methylpiperidino)-butyrophenone and its pharmaceutically acceptable salts
US3325521A (en) 1965-07-19 1967-06-13 Parke Davis & Co Halogenated cresol compounds and methods for their production
US3417087A (en) 1965-12-27 1968-12-17 Research Corp 3(aminopropionyl)benzothiophenes
CH479246A (de) * 1966-10-28 1969-10-15 Ciba Geigy Mittel zur Bekämpfung von phytopathogenen Pilzen und Bakterien
FR1588756A (en:Method) 1967-05-26 1970-03-16 Pepro
DE1679900A1 (de) * 1967-09-07 1971-04-08 Agfa Gevaert Ag Verfahren zum Verkleben von Polyesterfilmen
US3681445A (en) 1968-01-19 1972-08-01 Merck & Co Inc Substituted phenyl benzoic acid compounds
DE1989548U (de) 1968-03-29 1968-07-18 Karl Muenkel K G Zwei- oder mehrteiliger badezimmerschrank aus kunststoff.
US3721741A (en) 1968-10-28 1973-03-20 Ciba Geigy Ag Combatting phytopathogenic fungi on plants with sub-phytoloxic fungicidally effective amounts of herbicidal n-phenyl derivatives of 3,5-dihalo-salicylaldehyde
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3651085A (en) 1969-04-14 1972-03-21 Robins Co Inc A H 1-(omega-benzoylalkyl)-3-substituted pyrrolidines
US3703527A (en) 1969-06-04 1972-11-21 Hoffmann La Roche Preparation of mannich-bases
DE2021470A1 (de) 1970-05-02 1971-11-25 Cassella Farbwerke Mainkur Ag Piperazinderivate
FR2092133B1 (en:Method) 1970-05-06 1974-03-22 Orsymonde
US3714226A (en) 1970-06-09 1973-01-30 Merck & Co Inc Phenyl benzoic acid compounds
DE2142245C3 (de) * 1971-08-24 1980-09-04 Basf Ag, 6700 Ludwigshafen Farbstoffe auf der Basis von Imino-isoindolin, deren Herstellung und Verwendung als Pigmente für Lacke und zum Anfärben von Polyestermaterialien
US3969356A (en) 1971-09-13 1976-07-13 Kali-Chemie Aktiengesellschaft N-[3-(p-f-benzoyl)-propyl]-N'-[2.(nitro,nitro-el, or methoxyphenyl)-ethyl]-p
US3806526A (en) 1972-01-28 1974-04-23 Richardson Merrell Inc 1-aroylalkyl-4-diphenylmethyl piperidines
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3962459A (en) 1973-09-04 1976-06-08 Sandoz, Inc. Lipidemia treatment with p-phenoxy-alkylphenone compositions
US3873539A (en) 1973-10-03 1975-03-25 Sandoz Ag Substituted-4-aminoacetyl alkanoylphenones
US3992546A (en) 1973-10-18 1976-11-16 Ciba-Geigy Corporation 4-Piperidinobutyrophenones as neuroleptics
US4054570A (en) 1973-10-18 1977-10-18 Ciba-Geigy Corporation 4-Piperidinobutyrophenones
US3944064A (en) 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
US3995047A (en) 1973-12-14 1976-11-30 Eisai Co., Ltd. Propiophenone derivatives in the treatment of pathological muscular conditions
US3912755A (en) 1974-01-30 1975-10-14 Lilly Co Eli Preparation of pharmaceutical intermediates
US3931197A (en) 1974-02-08 1976-01-06 Richardson-Merrell Inc. Substituted piperidine derivatives
IL48319A0 (en) 1974-10-26 1975-12-31 Merck Patent Gmbh Araliphatic nitrogen compounds and a process for their preparation
US4028366A (en) 1975-01-20 1977-06-07 Sterling Drug Inc. 2-Naphthyl-lower-alkanoylamines
US4169892A (en) 1975-04-03 1979-10-02 Innothera 1-(benzothien-2'-yl)-3-morpholino propanones and therapeutic compositions containing same
US4066788A (en) 1975-10-03 1978-01-03 Richardson-Merrell Inc. Substituted benzaldehyde hypolipidemic agents
DE2557341A1 (de) 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4333941A (en) 1975-12-22 1982-06-08 The Dow Chemical Company Inhibition of enveloped viruses with phenyl ketones
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4015014A (en) 1976-03-17 1977-03-29 The Dow Chemical Company Method for the use of aryl azines as anthelmintics
DE2620254C2 (de) 1976-05-07 1984-03-15 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Hydroxybenzaldehyden
IT1068110B (it) 1976-08-13 1985-03-21 Montedison Spa Processo per la preparazione di aldeidi 2 idrossibenzoiche
US4072852A (en) * 1976-08-23 1978-02-07 Honeywell Inc. Digital computer monitoring and restart circuit
US4072582A (en) 1976-12-27 1978-02-07 Columbia Chemical Corporation Aqueous acid plating bath and additives for producing bright electrodeposits of tin
US4183553A (en) * 1977-02-04 1980-01-15 Ciba-Geigy Corporation Pressure- or heat-sensitive recording material and novel chromano compounds used therein
DE2718405A1 (de) 1977-04-26 1978-11-02 Boehringer Sohn Ingelheim Neue n- eckige klammer auf 1-(3-benzoylpropyl)-4-piperidyl eckige klammer zu -sulfonsaeureamide und verfahren zu deren herstellung
US4176198A (en) 1977-10-06 1979-11-27 William H. Rorer, Inc. Method of treatment
US4311841A (en) * 1977-11-21 1982-01-19 Petrolite Corporation Process of preparing hexahydropyrimidines
JPS54110321A (en) 1978-02-20 1979-08-29 Ajinomoto Co Inc Insecticide
JPS54125630A (en) 1978-02-22 1979-09-29 Nippon Zoki Pharmaceutical Co Novel propanone derivative*its manufacture and medical composition containing it as active component
JPS54163538A (en) 1978-06-13 1979-12-26 Sumitomo Chemical Co Production of salycilaldehydes
US4230727A (en) 1979-04-02 1980-10-28 William H. Rorer, Inc. Compositions and method of treatment
JPS606339B2 (ja) 1979-04-28 1985-02-18 ダイキン工業株式会社 フツ素化方法
DE3019496A1 (de) 1980-05-22 1981-11-26 Bayer Ag, 5090 Leverkusen Aminopropanol-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
DE3019497A1 (de) 1980-05-22 1981-11-26 Bayer Ag, 5090 Leverkusen Aminopropiophenon-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
FR2486523A1 (fr) 1980-07-11 1982-01-15 Rhone Poulenc Ind Procede de preparation de polyphenols comportant eventuellement un groupement aldehyde
SG56656G (en) * 1980-07-28 1987-03-27 Pfizer Hypoglycemic 5-substituted oxazolidine-2, 4-diones
DE3101750A1 (de) 1981-01-21 1982-08-26 Basf Ag, 6700 Ludwigshafen Verfahren zur kontinuierlichen herstellung von ethanol
US4381308A (en) 1981-04-23 1983-04-26 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4507268A (en) * 1982-01-25 1985-03-26 Henkel Corporation Solvent extraction
JPS58181971A (ja) 1982-04-15 1983-10-24 松下電器産業株式会社 自動車用キ−レスエントリ装置
JPS5944371A (ja) 1982-09-07 1984-03-12 Dainippon Pharmaceut Co Ltd １―フエニル―２―メチル―３―（１―ピロリジニル）―１―プロパノン誘導体
FR2534912B1 (fr) 1982-10-26 1985-06-28 Lafon Labor Nouveaux derives de (2,4,6-trimethoxyphenyl) - (3-piperidinopropyl) -cetone, utilisation en therapeutique et procede de preparation
DE3332780A1 (de) 1983-09-10 1985-03-28 Hoechst Ag, 6230 Frankfurt 6-sulfoxyphenolderivate, ihre herstellung und ihre verwendung als cytoprotekiva
US4686235A (en) 1983-10-12 1987-08-11 Merck & Co., Inc. Substituted cinnamyl-2,3-dihydrobenzofuran and analogs useful as anti-inflammatory agents
HU33131A (en:Method) 1984-01-26 1984-10-29
US4544663A (en) 1984-05-07 1985-10-01 Sandoz, Inc. Indolamine derivatives as anti-fertility agents
DE3436450A1 (de) 1984-10-05 1986-04-10 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von p-aminoethylketonen
US5057535A (en) 1985-04-11 1991-10-15 Nippon Kayaku Kabushiki Kaisha Derivatives of an aminoketone
FR2584715B1 (fr) 1985-07-10 1987-10-09 Lafon Labor Phenyl-(3-hexamethyleneiminopropyl)-cetone, procede de preparation et utilisation en therapeutique
FR2597864B1 (fr) 1986-04-28 1990-11-16 Lafon Labor Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique
US5571886A (en) 1986-12-23 1996-11-05 Shipley Company, Inc. Aromatic novolak resins
JPH0637389B2 (ja) 1986-12-26 1994-05-18 北陸製薬株式会社 頻尿治療剤
JPS63243085A (ja) * 1987-03-30 1988-10-07 Toray Ind Inc 新規スピロナフトピラン化合物
FR2618145B1 (fr) 1987-07-17 1989-11-24 Rhone Poulenc Chimie Procede de chloration selective de composes phenoliques
US4847429A (en) 1987-08-03 1989-07-11 Eastman Kodak Company Synthesis of phenylhydroquinones
US4927956A (en) 1987-09-16 1990-05-22 Hoechst Celanese Corporation 3,5-disubstituted-4-acetoxystyrene and process for its production
US5025036A (en) 1987-10-01 1991-06-18 Hoffmann-La Roche Inc. Catechol carboxylic acids
JPH0256469A (ja) * 1987-12-08 1990-02-26 Kumiai Chem Ind Co Ltd ピリミジン誘導体及び除草剤
JPH02264946A (ja) 1989-04-05 1990-10-29 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH085780B2 (ja) 1989-04-28 1996-01-24 呉羽化学工業株式会社 変形性関節症治療剤
EP0435827A3 (en) 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
DE4012008A1 (de) 1990-04-13 1991-10-17 Bayer Ag Verfahren zur herstellung von o-hydroxy-benzaldehyden
US5025006A (en) 1990-06-26 1991-06-18 Merck & Co., Inc. 2-biphenyl-carbapenem antibacterial agents
EP0467434A1 (en) 1990-06-26 1992-01-22 Merck & Co. Inc. 2-Biphenyl-carbapenem antibacterial agents
EP0464900A3 (en) 1990-06-26 1992-07-22 Merck & Co. Inc. 2-biphenyl-carbapenems
US5202355A (en) 1991-06-12 1993-04-13 Takasago Institute For Interdisciplinary Science Inc. Method of inhibiting aldose reductase in diabetic hosts using phenol derivatives
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
JPH05127335A (ja) 1991-10-14 1993-05-25 Fuji Photo Film Co Ltd 熱現像拡散転写型カラー感光材料
JPH05127330A (ja) 1991-11-06 1993-05-25 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
GB9127279D0 (en) 1991-12-23 1992-02-19 Ici Plc Heterocyclic derivatives
FR2689505B1 (fr) 1992-04-03 1995-06-09 Rhone Poulenc Chimie Procede d'hydroxylation de composes phenoliques.
CA2093778A1 (en) 1992-04-10 1993-10-11 George R. Brown Heterocyclic compounds
US5198422A (en) 1992-06-11 1993-03-30 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
GB9217723D0 (en) 1992-08-20 1992-09-30 Ici Plc Chemical process
JPH06135153A (ja) 1992-10-29 1994-05-17 Fuji Photo Film Co Ltd 感熱記録材料
FR2698353B1 (fr) 1992-11-25 1995-02-17 Rhone Poulenc Chimie Procédé de O-alkylation des composés phénoliques.
WO1994020473A1 (fr) 1993-03-11 1994-09-15 Yamanouchi Pharmaceutical Co., Ltd. Compose avec action antagoniste de la vasopressine
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
EP0650476B1 (en) 1993-04-07 2002-06-26 Otsuka Pharmaceutical Co., Ltd. Peripheral vasodilating agent containing n-acylated 4-amino piperidine derivatives as active ingredients
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
GB9308652D0 (en) 1993-04-27 1993-06-09 Wellcome Found Anti-inflammatory compounds
JPH06332264A (ja) 1993-05-24 1994-12-02 Hodogaya Chem Co Ltd 静電荷像現像用トナー
JPH0784415A (ja) 1993-06-25 1995-03-31 Hodogaya Chem Co Ltd 正帯電性トナー用摩擦帯電付与部材
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
HUT73813A (en) 1993-06-30 1996-09-30 Wellcome Found Anti-athero-sclerotic diaryl compounds, process to prepare them and pharmaceutical compositions contg. them
IT1266582B1 (it) 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
US5905080A (en) 1993-08-20 1999-05-18 Smithkline Beecham, P.L.C. Amide and urea derivatives as 5HT1D receptor antagonists
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd Piperidine derivatives their preparation and pharmaceutical compositions containing them
US5420362A (en) 1993-10-08 1995-05-30 Clairol, Inc. Synthesis of 2-methyl-1-naphthol
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
EP0886183A1 (en) 1993-12-17 1998-12-23 Fuji Photo Film Co., Ltd. Positive-working photoresist composition
GB9326008D0 (en) 1993-12-21 1994-02-23 Smithkline Beecham Plc Novel compounds
JPH09506885A (ja) 1993-12-21 1997-07-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ▲下１ｄ▼（抗うつ作用）活性を有するインドール、インドリンおよびキノリン誘導体
US5654260A (en) 1994-01-10 1997-08-05 Phillips Petroleum Company Corrosion inhibitor for wellbore applications
US5565416A (en) 1994-01-10 1996-10-15 Phillips Petroleum Company Corrosion inhibitor for wellbore applications
EP0802798A1 (en) 1994-02-23 1997-10-29 Chiron Corporation Method and compositions for increasing the serum half-life of pharmacologically active agents
ES2122564T3 (es) 1994-03-26 1998-12-16 Smithkline Beecham Plc Derivados de bifenilo como antagonistas del receptor 5ht1d.
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
WO1995030675A1 (en) 1994-05-06 1995-11-16 Smithkline Beecham Plc Biphenylcarboxamides useful as 5-ht1d antagonists
JPH10500960A (ja) 1994-05-28 1998-01-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄ−アンタゴニスト活性を有するアミド誘導体
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
DE4423061C1 (de) 1994-07-01 1996-01-18 Hoechst Ag Verfahren zur Herstellung von Biphenylen mit Palladacyclen als Katalysatoren
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5579110A (en) 1994-08-31 1996-11-26 Honeywell Inc. In-line multiple rotation sensor assembly
CA2158191A1 (en) 1994-09-16 1996-03-17 Junji Yokoi Method for preventing settlement of aquatic fouling organisms
US5599974A (en) 1994-09-19 1997-02-04 Center For Innovative Technology Aldehydic agents for allosteric modification of hemoglobin
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
GB9421003D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
US6214994B1 (en) 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US5705501A (en) 1994-11-17 1998-01-06 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-morpholinopropanones to treat Alzheimer's Disease
DE4444244A1 (de) * 1994-12-13 1996-06-20 Basf Ag Photochrome Spiroindoline
ES2153907T3 (es) 1994-12-22 2001-03-16 Smithkline Beecham Plc Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
ATE279406T1 (de) * 1995-01-12 2004-10-15 Glaxo Group Ltd Piperidinderivate mit tachykinin-antagonistischer wirkung
AU699727B2 (en) 1995-02-02 1998-12-10 Smithkline Beecham Plc Indole derivatives as 5-HT receptor antagonist
WO1996030333A1 (en) 1995-03-27 1996-10-03 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic agents
ES2201181T3 (es) 1995-04-04 2004-03-16 Encysive Pharmaceuticals Inc. Tienil-, furil-, pirrolil- y bifenilsulfonamidas y derivados de los mismos que modulan la actividad de endotelina.
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
GB9508637D0 (en) 1995-04-28 1995-06-14 Fujisawa Pharmaceutical Co New use
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5888941A (en) 1995-08-02 1999-03-30 J. Uriach & Cia. S.A. Carbozamides with antifungal activity
GB9519033D0 (en) 1995-09-18 1995-11-15 Smithkline Beecham Plc Treatment
FR2739098B1 (fr) 1995-09-25 1997-11-28 Rhone Poulenc Chimie Procede d'acylation d'un compose aromatique
GB9522845D0 (en) 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
JP2000502051A (ja) 1995-11-22 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ▲下１ｄ▼レセプターアンタゴニストとしての三環系スピロ化合物
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
JPH09149797A (ja) 1995-11-30 1997-06-10 Internatl Reagents Corp 酵素、抗原又は抗体の定量方法及び酵素活性測定用の基質
HUP9900143A3 (en) 1995-12-06 2000-04-28 Astra Pharmaceuticals Ltd King Pharmaceutically useful 3-pyridil-compounds
FR2744720B1 (fr) 1996-02-09 1998-04-10 Rhone Poulenc Chimie Procede d'hydroxylation de composes phenoliques
FR2745285B1 (fr) 1996-02-28 1998-04-10 Rhone Poulenc Chimie Nouveau catalyseur de c-alkylation d'un compose aromatique et son utilisation
FR2745287B1 (fr) 1996-02-28 1998-04-10 Rhone Poulenc Chimie Nouvelle composition catalytique et sa mise en oeuvre dans un procede d'acylation d'un compose aromatique
GB9605945D0 (en) 1996-03-21 1996-05-22 Smithkline Beecham Plc Novel compounds
GB9606370D0 (en) 1996-03-26 1996-06-05 Dormer Tools Sheffield Ltd Improvements in or relating to twist drills
JP2000507253A (ja) 1996-03-27 2000-06-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アザスピロ誘導体
GB9606396D0 (en) 1996-03-27 1996-06-05 Smithkline Beecham Plc Novel compounds
GB9607219D0 (en) 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
EP0845026A1 (de) 1996-06-19 1998-06-03 CALL, Hans-Peter Dr. Mehrkomponentensystem zur verwendung mit waschaktiven substanzen
NZ333800A (en) 1996-07-08 2000-08-25 Galderma Res & Dev Apoptosis inducing adamantyl derivatives and pharmaceutical uses
US6462064B1 (en) 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
IL128190A0 (en) 1996-07-31 1999-11-30 Shionogi & Co Novel p-terphenyl compounds
JP3202607B2 (ja) * 1996-08-01 2001-08-27 帝人株式会社 ２−（４−アルコキシ−３−シアノフェニル）チアゾール誘導体の製造法
DE19631131A1 (de) 1996-08-01 1998-02-05 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
FR2752165B1 (fr) * 1996-08-12 1998-10-09 Intertechnique Sa Equipement de protection respiratoire a mise en place rapide
US5668182A (en) 1996-08-19 1997-09-16 Virginia Commonwealth University Method of calming or sedating an animal with a hydroxy benzaldehyde compound
WO1998016504A2 (en) 1996-10-11 1998-04-23 Warner-Lambert Company SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS
FR2754533B1 (fr) 1996-10-14 1998-11-27 Rhodia Chimie Sa Procede de preparation selective d'un acide 2-hydroxybenzoique et d'un 4-hydroxybenzaldehyde et derives
FR2756278B1 (fr) 1996-11-22 1998-12-31 Rhodia Chimie Sa Procede de preparation d'un 4-hydroxybenzaldehyde et derives
FR2756279B1 (fr) 1996-11-27 1999-01-22 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
US6005009A (en) 1997-03-19 1999-12-21 Duke University Method of inhibiting fibrosis with pyridoxal benzoyl hydrazone and analogs thereof
CA2287255A1 (en) 1997-04-22 1998-10-29 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
US6288276B1 (en) 1997-05-21 2001-09-11 Henkel Kommanditgeselschaft Auf Aktien Salicylaldoximes and method of preparation
US6013841A (en) 1997-07-17 2000-01-11 Dakota Gasification Company Method for the conversion of 3- and 4-methylcatechol to benzaldehyde
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
US6174656B1 (en) 1997-09-30 2001-01-16 Fuji Photo Film Co., Ltd. Silver halide photographic light-sensitive material, aromatic aldehyde derivative compound, and image-forming method
US6124507A (en) 1997-12-10 2000-09-26 Union Carbide Chemicals & Plastics Technology Corporation Electron donors
SK9212000A3 (en) 1997-12-19 2001-02-12 Merck & Co Inc Arylthiazolidinedione derivatives, pharmaceutical compositions comprising the same and use thereof
EP0938025A1 (en) 1998-02-20 1999-08-25 Fuji Photo Film Co., Ltd. Heat developable color photographic light-sensitive material
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6340685B1 (en) 1998-05-22 2002-01-22 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
CA2335497A1 (en) 1998-06-25 1999-12-29 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
BR9912203A (pt) 1998-06-26 2001-04-10 Pfizer Productis Inc Processo melhorado para a preparação de aductos de base de schiff de aminas com o-hidroxialdeìdos e composições de matéria com base neles
WO2000002887A2 (en) 1998-07-10 2000-01-20 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
JP2000026438A (ja) 1998-07-14 2000-01-25 Fujimoto Brothers:Kk 新規な２−（ｎ−シアノイミノ）チアゾリジン−４− オン誘導体
RU2001106631A (ru) 1998-09-11 2004-03-20 Адзиномото Ко., Инк. (Jp) Производные бензола и их фармацевтическое применение
ATE289507T1 (de) 1998-10-08 2005-03-15 Allergan Inc Rar-antagonisten zur verhütung für männer
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
ES2290007T3 (es) 1999-05-20 2008-02-16 Ciba Specialty Chemicals Holding Inc. Compuestos de hidroxidifenil eter.
EP1201661A4 (en) 1999-07-15 2002-10-23 Sumitomo Pharma HETEROAROMATIC RING CONNECTIONS
AU6315300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
WO2001014314A1 (en) 1999-08-20 2001-03-01 Nippon Kayaku Kabushiki Kaisha Benzene derivatives having aromatic substituents and processes for the preparation thereof
EP1206442A4 (en) 1999-08-24 2004-12-29 Univ Virginia Commonwealth CHIRAL ALLOSTERIC MODIFIERS OF HEMOGLOBIN
UA74344C2 (uk) 1999-08-31 2005-12-15 Максіа Фармасьютікалз, Інк. Бензилідентіазолідиндіони і їх аналоги та їх застосування для лікування діабету
DE19942700C1 (de) 1999-09-07 2001-04-05 Consortium Elektrochem Ind Verfahren zur Herstellung cyclischer N-Hydroxydicarboximide
HUP0203448A3 (en) 1999-10-13 2005-07-28 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors and pharmaceutical compositions containing them
PT1142885E (pt) 1999-11-12 2007-02-28 Fujimoto Brothers Co Ltd Derivados de 2-(n-cianoimino)tiazolidin-4-ona
JP2001215669A (ja) 1999-11-25 2001-08-10 Fuji Photo Film Co Ltd 熱現像カラー感光材料
US6329129B1 (en) 1999-11-25 2001-12-11 Fuji Photo Film Co., Ltd. Heat-developable color light-sensitive material
KR20010074549A (ko) 2000-01-25 2001-08-04 고사이 아끼오 키랄 구리 착물, 이의 제조 방법 및 이를 이용한 비대칭합성
WO2001056962A1 (en) 2000-02-04 2001-08-09 Nihon Nohyaku Co., Ltd. Perfluoroisopropylbenzene derivatives
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2001316294A (ja) 2000-03-14 2001-11-13 Pfizer Prod Inc ｏ−バニリンおよびｏ−バニリン／テトラメチルクロマニルカルボン酸化合物の組み合わせの使用法
WO2001074762A2 (en) * 2000-04-03 2001-10-11 Phycogen, Inc. Arylsulfates and their use as enhancers or inhibitors of bioadhesion to surfaces
US6861444B2 (en) 2000-04-28 2005-03-01 Asahi Kasei Pharma Corporation Bicyclic compounds
WO2003024441A1 (en) 2001-09-14 2003-03-27 Shionogi & Co., Ltd. Novel use of tricyclic compound
JP2001335476A (ja) 2000-05-29 2001-12-04 Shionogi & Co Ltd 三環化合物の新規用途
TWI275589B (en) 2000-06-22 2007-03-11 Dow Agrosciences Llc 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds
CA2414198A1 (en) 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
EP1178036A1 (en) 2000-08-04 2002-02-06 Aventis Cropscience S.A. Fungicidal phenylimidate derivatives
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
DE10040051A1 (de) 2000-08-11 2002-02-21 Basf Ag Derivate des 4-(Trifluormethyl)-phenols sowie Derivate des 4-(Trifluormethylphenyl)-2-(tetrahydropyranyl)ethers und Verfahren zu ihre Herstellung
DE10046272A1 (de) 2000-09-19 2002-03-28 Merck Patent Gmbh Aminoheterocyclen (Faktor Xa Inhibitoren 14)
DE10047109A1 (de) 2000-09-22 2002-04-11 Bayer Ag Verfahren zur Herstellung von DELTA·1·-Pyrrolinen
DE10047111A1 (de) 2000-09-22 2002-04-11 Bayer Ag Verfahren zur Herstellung von DELTA·1·-Pyrrolinen
EP1195166B1 (en) 2000-10-04 2007-07-25 Astellas Pharma Inc. Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension
WO2002041882A2 (en) 2000-11-22 2002-05-30 Novartis Ag Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
WO2002050001A2 (en) 2000-12-20 2002-06-27 Warner-Lambert Company Non-halogenated naphthol compounds and antimicrobial compositions containing the same
JP2002275165A (ja) 2001-01-12 2002-09-25 Sumitomo Pharmaceut Co Ltd トリアゾール誘導体
WO2002055497A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
DE10102341A1 (de) 2001-01-19 2002-08-08 Ralf Steffens Profilkontur einer Schraubenspindelpumpe
JP2004525118A (ja) * 2001-01-22 2004-08-19 アルパイダ　アーゲー 新規ヒドラゾン類
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
US20030022923A1 (en) 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
AU2002254171A2 (en) 2001-03-08 2002-09-24 Incyte San Diego, Inc. RXR activating molecules
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP2004526752A (ja) 2001-04-09 2004-09-02 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト Δ１−ピロリン類の製造方法
CA2443672C (en) 2001-04-12 2011-03-29 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
US7326700B2 (en) 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
PL367680A1 (en) 2001-06-28 2005-03-07 Pfizer Products Inc. Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
US6605620B1 (en) 2001-08-30 2003-08-12 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
US6867221B2 (en) 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
EP1432694A1 (en) 2001-10-05 2004-06-30 Wyeth Stereospecific process for the synthesis of 2-yl chroman derivatives
DE10150335A1 (de) 2001-10-15 2003-04-24 Degussa Neue chirale Liganden und deren Übergangsmetallkomplexe sowie deren katalytische Anwendung
JP4581321B2 (ja) 2001-10-23 2010-11-17 住友化学株式会社 不飽和有機化合物誘導体の製造方法
US20060287337A1 (en) 2001-11-09 2006-12-21 Proteologics, Inc. Trans-golgi network-associated processes, methods and compositions related thereto
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
JP2003229174A (ja) * 2002-01-31 2003-08-15 Sanyo Electric Co Ltd フィルム状外装体を用いた非水電解質二次電池
US6919343B2 (en) 2002-02-08 2005-07-19 Merck & Co., Inc. N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
CA2473778A1 (en) 2002-02-08 2003-08-14 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives
BR0308537A (pt) 2002-03-20 2005-02-09 Metabolex Inc Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
CA2480880C (en) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
MY134200A (en) 2002-04-12 2007-11-30 Kowa Co Method for treating cancer
DE10216368A1 (de) 2002-04-12 2003-10-16 Henkel Kgaa Arylsulfatase-Inhibitoren in Deodorantien und Antitranspirantien
US20030229149A1 (en) 2002-05-28 2003-12-11 Werner Baschong Anti-inflammatory agents
GB0216252D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
GB0216233D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
GB0216224D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
US20040034064A1 (en) 2002-08-06 2004-02-19 Kuduk Scott D. 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives
US20040044041A1 (en) 2002-08-06 2004-03-04 Kuduk Scott D. 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives
US20040063761A1 (en) 2002-08-06 2004-04-01 Kuduk Scott D. 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
AU2003302736A1 (en) 2002-12-03 2004-06-30 Bristol-Myers Squibb Company Process for removing metals from liquids
HUE025683T2 (hu) 2002-12-03 2016-04-28 Pharmacyclics Llc VIIA faktor inhibitor 2-(2-hidroxi-bifenil-3-il)-1H-benzoimidazol-5-karboxamidin-származékok
EP2179987B1 (en) 2002-12-04 2013-02-13 Virginia Commonwealth University Use of heterocyclic carbaldehyde derivatives against sickle cell anemia
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
JP4464280B2 (ja) 2002-12-06 2010-05-19 興和株式会社 エリスロポエチン産生促進剤
DE10257357A1 (de) 2002-12-09 2004-06-24 Bayer Ag Fluorhaltige Benzaldehyde
US20040181075A1 (en) 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
EP1608623B1 (en) * 2003-02-05 2011-01-19 Desi Raymond Richardson Metal ion chelators and therapeutic use thereof
JP4331954B2 (ja) 2003-02-13 2009-09-16 株式会社リコー ユニット支持装置および画像形成装置
JP2007527361A (ja) 2003-02-28 2007-09-27 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド エレクトロルミネセンス素子
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
CA2519677A1 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocycles as sodium channel blockers
WO2004084890A1 (en) 2003-03-26 2004-10-07 Crc For Asthma Limited Therapeutic and prophylactic compositions and uses therefor
EP1615895A4 (en) 2003-04-03 2007-11-07 Merck & Co Inc BIARYLSUBSTITUTED PYRAZOLE AS SODIUM CHANNEL BLOCKER
EP1628665A2 (en) 2003-04-16 2006-03-01 Amgen Inc. 3-phenyl-4-(pyrimidin-2-yl)-6-(piperidin-4-yl) derivatives and related compounds as tnf-alpha and il-1 inhibitors for the treatment of inflammations
CN1805945A (zh) 2003-04-18 2006-07-19 麦克公司 作为钠通道阻滞剂的联芳基取代的噻唑、噁唑和咪唑
EP1631561B1 (en) 2003-05-07 2010-08-18 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
WO2004098582A2 (en) 2003-05-07 2004-11-18 The University Court Of The University Of Aberdeen Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions
US20040223912A1 (en) 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
GB0312654D0 (en) 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
FR2857010B1 (fr) 2003-07-01 2005-09-16 Servier Lab Nouveaux derives bicycliques alkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2532248A1 (en) 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
DE602004030689D1 (de) 2003-07-23 2011-02-03 Synta Pharmaceuticals Corp Verbindungen gegen entzündungen und immun-relevante verwendungen
EP1653148B1 (en) 2003-07-25 2018-05-02 Toyota Jidosha Kabushiki Kaisha Gas supply system
MXPA06001739A (es) 2003-08-14 2006-05-12 Asahi Kasei Pharma Corp Derivado de acido arilalcanoico substituido y uso del mismo.
KR20060066738A (ko) 2003-09-05 2006-06-16 시바 스페셜티 케미칼스 홀딩 인크. 전계발광 장치
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
WO2005034953A1 (ja) 2003-10-10 2005-04-21 Kowa Co., Ltd. 血管新生抑制薬
US6990935B2 (en) 2003-10-27 2006-01-31 Borgwarner Inc. Pivoting lifter control system using spool valve and check valve to recirculate oil
CA2540342A1 (en) 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
AR046698A1 (es) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo
EP1687856B1 (en) 2003-11-26 2007-02-28 Ciba SC Holding AG Electroluminescent devices comprising 2-(p-triphenyl)-3-phenyl-pyrazine derivatives
US7119208B2 (en) 2003-12-03 2006-10-10 Virginia Commonwealth University Anti-sickling agents
US7538241B2 (en) 2003-12-26 2009-05-26 Kyowa Hakko Kogyo Co., Ltd. Hsp90 family protein inhibitors
US20050165025A1 (en) 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
US7501510B2 (en) 2004-03-26 2009-03-10 The University Of Hong Kong Thiourea compositions and uses thereof
FR2868417B1 (fr) 2004-04-02 2006-06-23 Rhodia Chimie Sa Procede de formation d'une liaison carbone-carbone
JP2006151946A (ja) 2004-04-30 2006-06-15 Konishi Kagaku Ind Co Ltd ジアリール誘導体の製造方法
GB0412874D0 (en) 2004-06-09 2004-07-14 Pfizer Ltd Novel pharmaceuticals
JP5020073B2 (ja) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
DE102004035322A1 (de) 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
FR2874611B1 (fr) 2004-08-31 2006-11-17 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006029850A1 (en) * 2004-09-14 2006-03-23 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
US20060094747A1 (en) 2004-10-28 2006-05-04 The Institute For Pharmaceutical Discovery, L.L.C. Substituted carboxylic acids
JP2006135153A (ja) 2004-11-08 2006-05-25 Canon Inc ビルドアッププリント配線基板および電子部品との接合構造
WO2006071538A2 (en) 2004-12-13 2006-07-06 Neurogen Corporation Substituted biaryl analogues
WO2006074919A2 (de) 2005-01-12 2006-07-20 Curacyte Discovery Gmbh 3 -AMINO- 6-ARYL (BZW.6-HETEROARYL) -THIENO [2 , 3-B] PYRIDIN-2-CARBONSÄUREAMIDE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN UND IHRE VERWENDUNG ALS INHIBITOREN DER TNFα-FREISETZUNG
JP3839454B2 (ja) 2005-02-07 2006-11-01 三菱電機株式会社 内燃機関の制御装置
US20090123563A1 (en) * 2005-02-07 2009-05-14 Novo Nordisk A/S Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
ES2529047T3 (es) 2005-02-11 2015-02-16 Bayer Intellectual Property Gmbh Composición fungicida que comprende un derivado de piridilmetilbenzamida y un derivado de tiazolocarboxamida
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US7691848B2 (en) 2005-03-02 2010-04-06 Wyeth Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
WO2006093353A1 (ja) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
DE102005009705A1 (de) 2005-03-03 2006-09-07 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
TW200702363A (en) 2005-04-05 2007-01-16 Sumitomo Chemical Co Crosslinked polymer electrolyte and method for producing the same
US7482027B2 (en) 2005-04-30 2009-01-27 Angiolab, Inc. Composition for the prevention or treatment of diseases associated with angiogenesis
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2006124523A1 (en) 2005-05-12 2006-11-23 Wyeth Pyrrolobenzodiazepines and heteroaryl, aryl and cycloalkylamino ketone derivatives as follicle stimulating hormone receptor -(fish-r) antagonists
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
AU2006247601A1 (en) 2005-05-12 2006-11-23 Wyeth Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists
US20060258691A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
RU2007146444A (ru) 2005-05-13 2009-06-20 Лексикон Фармасьютикалз, Инк. (Us) Полициклические соединения и способы их применения
WO2006124865A2 (en) 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
MX2007015643A (es) 2005-06-09 2008-02-15 Wyeth Corp Pirrolobenzodiazepinpiridincarboxamidas y derivados como antagonistas de receptor de hormona estimulante del foliculo.
JP2009502843A (ja) 2005-07-29 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー アザベンズイミダゾール誘導体、それらの製造、及び抗癌剤としての使用
WO2007020888A1 (ja) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited 脳・神経細胞保護剤および睡眠障害治療薬
EP1922383A1 (en) 2005-08-26 2008-05-21 Koninklijke Philips Electronics N.V. Substrate material for handling and analysing samples
WO2007027878A2 (en) 2005-08-31 2007-03-08 Emergent Product Development Gaithersburg Inc. 4-substituted 2-aryloxyphenol derivatives as antibacterial agents
JP2009507896A (ja) 2005-09-13 2009-02-26 パラウ・フアルマ・ソシエダツド・アノニマ ヒスタミンｈ４受容体活性の調節剤としての２−アミノピリミジン誘導体
BRPI0615987A2 (pt) 2005-09-13 2012-04-10 Bayer Cropscience Ag composição fungicida e método de controle curativo ou preventivo dos fungos fitopatogênicos de plantas ou safras
JP2007084415A (ja) 2005-09-17 2007-04-05 Chikosha:Kk 木材チップを混入した軽量注入材。
WO2007034277A1 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
JP2007084454A (ja) 2005-09-20 2007-04-05 Fujifilm Corp スルホニウム化合物の製造方法
DE102005045132A1 (de) 2005-09-22 2007-03-29 Archimica Gmbh Verfahren zur Herstellung von 2-Arylcarbonylverbindungen, 2-Arylestern und 2-Arylnitrilen sowie ihrer heteroaromatischen Analoga
GB0519651D0 (en) 2005-09-27 2005-11-02 Univ Nottingham Ferrocenyl phosphite ligands for asymmetric catalysis and a method for their production
CN1958568B (zh) 2005-11-03 2011-04-13 中国科学院上海药物研究所 一类预防或治疗幽门螺杆菌感染化合物、其制法和用途
US8017331B2 (en) 2005-11-04 2011-09-13 Mannkind Corporation IRE-1α substrates
JP2009516691A (ja) 2005-11-21 2009-04-23 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド Ｑｔ間隔延長およびこれに伴う疾病の治療
CA2631905A1 (en) 2005-12-01 2007-06-07 William E. Klunk Isotopically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins
EP1986985B1 (en) 2005-12-02 2010-09-01 Finorga Sas Intermediates and process for the preparation of aromatic derivatives of 1-adamantane
JP2009517456A (ja) 2005-12-02 2009-04-30 フィノルガ ソシエテ パル アクションス シンプリフィ １−アダマンタンの芳香族誘導体の調製方法
WO2007067593A2 (en) 2005-12-05 2007-06-14 Merck & Co., Inc. Self-emulsifyng formulations of cetp inhibitors
AR057218A1 (es) 2005-12-15 2007-11-21 Astra Ab Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
US7691902B2 (en) 2005-12-28 2010-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
AU2006332681B2 (en) 2005-12-30 2011-04-07 Merck Sharp & Dohme Corp. 1, 3-oxazolidin-2-one derivatives useful as CETP inhibitors
WO2007077457A2 (en) 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
GB0601031D0 (en) 2006-01-18 2006-03-01 Novartis Ag Organic compounds
WO2007092930A2 (en) 2006-02-08 2007-08-16 Regents Of The University Of California Method of treatment for mycobacterium tuberculosis
AU2007220040A1 (en) * 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Methods to identify inhibitors of the unfolded protein response
US20080051445A1 (en) 2006-03-08 2008-02-28 National Institute Of Immunology. 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways
WO2007115409A1 (en) 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US20070249607A1 (en) 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
US20080064717A1 (en) 2006-05-19 2008-03-13 Rajesh Iyengar Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
WO2008002246A1 (en) 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
AU2007273333B2 (en) 2006-07-11 2010-07-08 Daewoong Pharmaceutical Co., Ltd. Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8071631B2 (en) 2006-08-16 2011-12-06 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
US20080076800A1 (en) 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
WO2008030752A2 (en) 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
WO2008037266A1 (en) 2006-09-25 2008-04-03 Universite Libre De Bruxelles Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
WO2008042892A2 (en) 2006-10-02 2008-04-10 N.V. Organon Fatty acid amide hydrolase inhibitors for energy metabolism disorders
JP4827986B2 (ja) 2007-06-08 2011-11-30 マンカインド コーポレ−ション ＩＲＥ−１αインヒビター
JP5127330B2 (ja) 2007-07-12 2013-01-23 日立造船株式会社 光電変換素子およびその製造方法
JP5127335B2 (ja) 2007-07-17 2013-01-23 三井造船株式会社 接続部の構造、バラ積み貨物荷役装置及び接続部の気密保持方法
JP2009149797A (ja) 2007-12-21 2009-07-09 Tohoku Carbon Kk 木炭粉含有塗料組成物及びその塗装方法
USD675543S1 (en) 2011-07-26 2013-02-05 Gizmode, LLC Moisture detection device
JP6135153B2 (ja) 2013-01-30 2017-05-31 井関農機株式会社 管理機

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56138179A (en) * 1980-02-04 1981-10-28 Anvar 2-nitronaphthofuran derivative, manufacture and cell growth regulant containing same
JP2001518890A (ja) * 1997-04-08 2001-10-16 サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク （セ エン エール エス） Ｈｉｖインテグラーゼの阻害剤としてのキノリン誘導体
JP2004534779A (ja) * 2001-05-30 2004-11-18 エルジー ライフサイエンス リミテッド 疾病治療用プロテインキナーゼ阻害剤
WO2004037816A1 (en) * 2002-10-28 2004-05-06 Chugai Seiyaku Kabushiki Kaisha Benzofuran compounds having antitumor activity
WO2007056155A1 (en) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011121964A (ja) * 2007-06-08 2011-06-23 Mannkind Corp ＩＲＥ−１αインヒビター
JP2014055129A (ja) * 2007-06-08 2014-03-27 Mannkind Corp ＩＲＥ−１αインヒビター

Also Published As

Publication number Publication date
EP2520561B1 (en) 2016-02-10
CN102015606B (zh) 2015-02-04
MX2009013332A (es) 2010-01-25
CN103450077A (zh) 2013-12-18
US20140080832A1 (en) 2014-03-20
JP2010529147A (ja) 2010-08-26
JP2011121964A (ja) 2011-06-23
ES2569660T3 (es) 2016-05-12
CN103450077B (zh) 2016-07-06
US20160168116A1 (en) 2016-06-16
US7858666B2 (en) 2010-12-28
EP2155643A1 (en) 2010-02-24
JP2015091863A (ja) 2015-05-14
US8614253B2 (en) 2013-12-24
JP5941173B2 (ja) 2016-06-29
CA2690913A1 (en) 2008-12-18
CA2963784A1 (en) 2008-12-18
ES2601856T3 (es) 2017-02-16
EP2155643B1 (en) 2016-08-10
JP5684585B2 (ja) 2015-03-11
US9546149B2 (en) 2017-01-17
EP2532643A1 (en) 2012-12-12
US9241942B2 (en) 2016-01-26
US20110065162A1 (en) 2011-03-17
HK1176601A1 (en) 2013-08-02
CA2690913C (en) 2017-05-23
JP2014055129A (ja) 2014-03-27
EP3150589A1 (en) 2017-04-05
US20090186893A1 (en) 2009-07-23
US20170152206A1 (en) 2017-06-01
CN102015606A (zh) 2011-04-13
EP2520561A1 (en) 2012-11-07
WO2008154484A1 (en) 2008-12-18
US9981901B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
JP5941173B2 (ja) ＩＲＥ−１αインヒビター
JP2016185947A (ja) ＩＲＥ−１αインヒビター
HK1192249A (en) Ire-1a inhibitors
HK1179602A (en) Ire-1a inhibitors
HK1192249B (en) Ire-1a inhibitors
HK1176601B (en) Ire-1a inhibitors
HK1139383B (en) Ire-1a inhibitors
HK1169329B (en) Ire-1 alpha inhibitors
HK1169329A (en) Ire-1 alpha inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110124

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110124

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110831

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110913

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140922

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4827986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees